Europe's Committee for Medicinal Products for Human Use (CHMP) recommends that the European Medicines Agency (EMA) approve Bristol-Myers Squibb's (BMY) Eliquis (apixaban) for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE in adults.
Eliquis is an oral selective Factor Xa inhibitor, a key blood clotting protein. It decreases thrombin generation and blood clot formation. It is currently approved the U.S., E.U., Japan and other countries as a treatment to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is approved for the prophylaxis of DVT which can lead to PE in adult patients who have undergone hip or knee replacement surgery in the U.S. and E.U. and other countries (except Japan).